- Pfizer Canada announced that Prevnar 20 (20-valent pneumococcal conjugate vaccine) has been selected for Québec’s publicly funded pediatric pneumococcal immunization program. Since May 2026, infants in the province have been routinely offered the vaccine, making Québec the second Canadian province, after British Columbia, to adopt Prevnar 20.
- The Comité sur l’immunisation du Québec recommends Prevnar 20 as the preferred vaccine for routine infant and child immunization, providing the broadest serotype coverage against severe pneumococcal disease through public funding.
- Pneumococcal disease can cause serious infections, including sepsis, meningitis, and pleural empyema, contributing to significant illness and healthcare burden in children. The broader vaccine coverage aims to strengthen disease prevention and reduce hospitalizations.
- Pfizer welcomed Québec’s decision and said it will continue working with other provinces to expand access to Prevnar 20 and reduce disparities in pediatric pneumococcal vaccination across Canada.
Takeaways:
The decision strengthens Pfizer’s foothold in Canada’s publicly funded pediatric pneumococcal market by making Prevnar 20 the standard for infants in two large provinces, which can drive higher uptake, streamline procurement, and create momentum for other provinces to follow. Broader serotype coverage and public funding also improve the value proposition for payers and providers, potentially reducing disease burden and hospitalizations while cementing Prevnar 20’s leadership over narrower-valent competitors in the routine childhood schedule.
Source: CA Newswire
